ArticleMicrobiology spectrum2025
Diagnostic accuracy of smear microscopy, mycobacterial culture, and GeneXpert MTB/RIF assay for diagnosis of subclinical tuberculosis: a retrospective multicenter study.
Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Subclinical tuberculosis (TB) challenges public health interventions. This retrospective multicenter study aimed to evaluate the diagnostic efficacy of smear microscopy, mycobacterial culture, and GeneXpert MTB/RIF assay (Xpert) for subclinical TB and identify its proportion and risk factors in China. Among 560 participants diagnosed with TB, 309 (55.18%) patients had active TB, and 251 (44.82%) had subclinical TB. For subclinical TB diagnosis, smear microscopy, mycobacterial culture, and Xpert had detection rates of 11.5%, 40.6%, and 40.6%, respectively, which were significantly lower than those for active TB (25.2%, 59.2%, and 63.7% respectively). Conversely, interferon-γ release assays (IGRA) showed similar detection rates for both subclinical (85.7%) and active TB (84.1%). Age groups of 40-60 years and under 40 years, as well as employed individuals had higher risks of subclinical TB. To conclude, about 45% of TB patients were subclinical in our study. Microbiologic tests had lower diagnostic sensitivities for subclinical TB than for active TB, while IGRA positivity rates were comparable between asymptomatic and symptomatic TB patients, highlighting the potential of antigen-specific immune response in the diagnosis of these asymptomatic individuals. Further clinical trials are warranted to investigate the diagnostic flow chart in individuals with subclinical TB. IMPORTANCE: Subclinical tuberculosis (TB) poses a major challenge to public health interventions, especially in the wake of the COVID-19 pandemic. However, a substantial proportion of individuals have absence or non-recognized symptoms, which put great pressure on clinical diagnosis. In this study, we conducted a retrospective multicenter study to assess the performance of smear microscopy, mycobacterial culture, and GeneXpert MTB/RIF (Xpert) in diagnosis of subclinical TB. We also aimed to determine the proportion and risk factors of subclinical TB in China in order to accelerate progress towards global milestones and targets for the End TB Strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.